Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 34 for:    msc | Amyotrophic Lateral Sclerosis

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04514952
Expanded Access Status : No longer available
First Posted : August 17, 2020
Last Update Posted : October 23, 2020
Sponsor:
Collaborator:
Hope Biosciences Stem Cell Research Foundation
Information provided by (Responsible Party):
Hope Biosciences

Tracking Information
First Submitted Date August 12, 2020
First Posted Date August 17, 2020
Last Update Posted Date October 23, 2020
 
Descriptive Information
Brief Title Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis
Official Title Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis
Brief Summary The drug for this submission is Hope Biosciences' autologous, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Amyotrophic Lateral Sclerosis (ALS). Stem cells have become a promising tool for the treatment of inflammatory and neurodegenerative conditions, including autoimmune diseases, traumatic brain injury, Parkinson's disease, and Alzheimer's disease.
Detailed Description

Once the eligibility is confirmed, approximately 1-2 weeks after the screening visit, the subject will return for the baseline/first infusion visit. Subsequent treatments will occur 2 weeks apart for 18 weeks, for a total of 10 infusions. Follow-up visits will occur at 22 weeks, 26 weeks and 39 weeks. End of study visit will occur at 52 weeks.

Baseline/Infusion 1 Visit

  1. A verification of patient consent will be verbally performed and included in the progress note.
  2. Review of medical history, and concomitant medications.
  3. Physical exam + ALS Functional Rating Scale-Revised (ALSFRS-R)
  4. Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)
  5. Weight measurement
  6. Blood samples will be collected for safety and efficacy assessments:

    • Hematology
    • Chemistry
    • Coagulation Panel
    • Proinflammatory Cytokines (IL-2, IL-6, TNF-a)
    • C- Reactive Protein (CRP)
  7. The HB-adMSCs will be administered and the patient closely observed:

    • One intravenous infusion of HB-adMSCs (2x108 cells) to last 1 hour:

    • Volume: 250 ml of Saline Solution 0.9%.
    • Rate: 83gts/min (250ml/h)
  8. The subject will then be monitored for a minimum of 2hr after infusion as follows:

    • Measure Vital signs at minute 0 of infusion.
    • Measure Vital signs at minute 15 after IV infusion.
    • Measure Vital Signs at minute 30 after IV infusion.
    • Measure Vital signs at minute 60 after IV infusion.
    • Measure Vital signs at minute 120 after IV infusion. (Vital signs will be recorded more frequently if clinically indicated).
  9. Adverse event monitoring
  10. 24 hrs. Telephone encounter. The subject will be contacted by telephone the following day after the infusion visit to determine if any adverse events have occurred.
  11. ALS-specific Quality of Life Survey-revised (ALSSQOL-R)
  12. A video recording will be made with the purpose to capture patient's overall status (gait, range of motion assessments, etc.).

One week following infusion, PI will perform an assessment to determine patient status and discuss any changes since previous infusion.

Infusion Visits Week 2,6,10,14 and 18

  1. Review and update medical history
  2. Update concomitant medications list
  3. Weight measurement
  4. Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)
  5. Physical examination + ALS Functional Rating Scale-Revised (ALSFRS-R)
  6. The HB-adMSCs will be administered and the patient closely observed:

    • One intravenous infusion of HB-adMSCs (2x108 cells) to last 1 hour:

    • Volume: 250 ml of Saline Solution 0.9%.
    • Rate: 83gts/min (250ml/h)
  7. Adverse event monitoring
  8. 24 hrs. Telephone encounter. The subject will be contacted by telephone the following day after the infusion visit to determine if any adverse events have occurred.

Infusion Visits Week 4, 8, 12, and 16

  1. Review and update medical history
  2. Update concomitant medications list
  3. Weight measurement
  4. Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)
  5. Physical examination and ALS Functional Rating Scale-Revised (ALSFRS-R)
  6. Blood samples will be collected for safety and efficacy assessments:

    • Hematology
    • Chemistry
    • Coagulation Panel
    • Proinflammatory Cytokines (IL-2, IL-6, TNF-a)
    • C - Reactive Protein
  7. The HB-adMSCs will be administered and the patient closely observed:

    • One intravenous infusion of HB-adMSCs (2x108 cells) to last 1 hour:

    • Volume: 250 ml of Saline Solution 0.9%.
    • Rate: 83gts/min (250ml/h)
  8. ALS-specific Quality of Life Survey-revised (ALSSQOL-R)
  9. Adverse event monitoring
  10. 24 hrs. Telephone encounter. The subject will be contacted by telephone the following day after the infusion visit to determine if any adverse events have occurred.

Follow-Up Visit Week 22

  1. You will be asked about your current health and medical history (if any changes since last study visit or telephone call).
  2. You will be asked if there was any change in the medication list you have previously provided (Concomitant medication list).
  3. Your blood pressure, heart rate, respiration rate, temperature, oxygen saturation and weight will be measured.
  4. The doctor will perform a physical examination driven by the signs and/or symptoms you experience, if any.
  5. The doctor will perform tests including the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) to measure the symptoms of ALS Disease on how you are able to perform.
  6. You will be asked to complete the Amyotrophic Lateral Sclerosis-Specific Quality of Life-Revised (ALSSQOL-R) questionnaire to assess the impact of Amyotrophic Lateral Sclerosis on your quality of life.
  7. You will be reminded to stay on your stable regimen of treatment throughout the study

Follow-Up Visit Week 26

  1. You will be asked about your current health and medical history.
  2. You will be asked about the medicines that you have taken and are currently taking for Amyotrophic Lateral Sclerosis and for other health issues.
  3. Your blood pressure, heart rate, respiration rate, oxygen saturation, temperature, and weight will be measured.
  4. The doctor will perform a complete physical examination.
  5. The doctor will perform tests including the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) to measure the symptoms of ALS Disease on how you are able to perform.
  6. You will be asked to complete the Amyotrophic Lateral Sclerosis-Specific Quality of Life-Revised (ALSSQOL-R) questionnaire to assess the impact of Amyotrophic Lateral Sclerosis on your quality of life.
  7. Laboratory test will be done. About 6 tablespoons of blood will be taken from your arm using a needle. Your blood will be tested to measure your overall health and efficacy markers (TNF-a, IL-6, IL-2 and C - Reactive Protein).
  8. You will be given an order for a Chest X ray (PA single view) and Magnetic Resonance Imaging to be performed. If within 7 days of the End of study visit you have undergone any or both, such reports would suffice this requirement.
  9. An Electrocardiogram (ECG) will be performed to evaluate cardiac function.
  10. An Electromyogram (EMG) will be performed to evaluate neuromuscular function.
  11. A video documenting of yourself walking and sitting will be performed.

Follow-Up Visit Week 39

  1. You will be asked about your current health and medical history (if any changes since last study visit or telephone call).
  2. You will be asked if there was any change in the medication list you have previously provided (Concomitant medication list).
  3. Your blood pressure, heart rate, respiration rate, temperature, oxygen saturation and weight will be measured.
  4. The doctor will perform a physical examination driven by the signs and/or symptoms you experience, if any.
  5. Laboratory test will be done. About 6 tablespoons of blood will be taken from your arm using a needle. Your blood will be tested to measure your overall health and efficacy markers (TNF-a, IL-6, IL-2 and C - Reactive Protein).
  6. The doctor will perform tests including the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) to measure the symptoms of ALS Disease on how you are able to perform.
  7. You will be asked to complete the Amyotrophic Lateral Sclerosis-Specific Quality of Life-Revised (ALSSQOL-R) questionnaire to assess the impact of Amyotrophic Lateral Sclerosis on your quality of life.
  8. You will be reminded to stay on your stable regimen of treatment throughout the study

End of Study Visit Week 52

  1. Review and update medical history
  2. Review and update concomitant medications list
  3. Weight measurement
  4. Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)
  5. Physical examination + ALS Functional Rating Scale-Revised (ALSFRS-R)
  6. Blood samples will be collected for safety and efficacy assessments:

    • Hematology
    • Coagulation Panel
    • Proinflammatory Cytokines (IL-2, IL-6, TNF-a)
    • C - Reactive Protein
  7. ALS-specific Quality of Life Survey-revised (ALSSQOL-R)
  8. Chest X-Ray (PA single view)
  9. Electromyogram (EMG)
  10. Magnetic Resonance Imaging (MRI)
  11. Adverse event monitoring
  12. A video recording will be made with the purpose to capture patient's overall status (gait, range of motion assessments, etc.).
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Amyotrophic Lateral Sclerosis
Intervention Drug: HB-adMSCs
Hope Biosciences autologous adipose-derived mesenchymal stem cells
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status No longer available
Eligibility Criteria

Inclusion Criteria:

  1. Documented diagnosis of Amyotrophic Lateral Sclerosis.
  2. Capable of giving informed consent (signed, verbal or assent as applicable and as listed in the protocol)

Exclusion Criteria:

  1. Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSCs administration.
  2. Any abnormal, inexplicable laboratory result that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSCs administration.
  3. Participation in other interventional research studies within the past 30 days.
  4. Unwillingness to return for follow-up visits.
Sex/Gender
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04514952
Other Study ID Numbers Amyotrophic Lateral Sclerosis
Responsible Party Hope Biosciences
Study Sponsor Hope Biosciences
Collaborators Hope Biosciences Stem Cell Research Foundation
Investigators
Principal Investigator: Rajiv Thakur, MD River Oaks Hospital and Clinics
PRS Account Hope Biosciences
Verification Date October 2020